MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
RZLT - Rezolute Inc
$11.50
0.01(0.09%)9:00:00 PM 2/26/2021
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
leak data
Peers

Related Peers

Stock news

    02/10/2021RZLT
    Rezolute Reports Second Quarter Fiscal 2021 Financial Results

    REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), today announced its financial results for the quarter ended December 31, 2020. Recent Business Highlights Phase 2b study of RZ358 continues to enroll congenital hyperinsulinism (HI) patients worldwide – The RIZE Phase 2b study of RZ358 for the treatment of congenital HI continues to enroll patients, with study completion expected in the second half of 2021. RZ358 is an allosteric modulator of the insulin recep...

    01/12/2021RZLT
    Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema

    RZ402 is a plasma kallikrein inhibitor being investigated as a potential once-daily, oral therapy for DME Trial initiation marks expansion of the Company’s pipeline to a second clinical-stage program, reinforcing its commitment to advancing novel therapies for patients with serious unmet metabolic diseasesREDWOOD CITY, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), today announced the initiation of dosing in a Phase 1 first-in-human clinical study of RZ402, an investig...

    01/11/2021RZLT
    What Is The Ownership Structure Like For Rezolute, Inc. (NASDAQ:RZLT)?

    If you want to know who really controls Rezolute, Inc. ( NASDAQ:RZLT ), then you'll have to look at the makeup of its...

    12/28/2020RZLT
    Rezolute Announces Change of Transfer Agent

    REDWOOD CITY, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq:RZLT), focused on advancing therapies for rare, metabolic and life-threatening diseases, announced today the appointment of IssuerDirect as the Company’s registrar and transfer agent and shareholder support provider. IssuerDirect will now be responsible for all transfers of Rezolute shares rather than VStock Transfer, LLC. Shareholders need take no action related to this transaction. About Rezolute, Inc. Rezolute is...

    12/3/2020RZLT
    FDA Clears Rezolute’s IND Application for RZ402

    RZ402 is an orally available plasma kallikrein inhibitor in development for the treatment of diabetic macular edemaREDWOOD CITY, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq:RZLT), focused on advancing therapies for rare, metabolic and life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for RZ402, an orally available plasma kallikrein inhibitor, which is in development for the tr...

    11/19/2020RZLT
    Rezolute to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

    REDWOOD CITY, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq:RZLT), a clinical stage biopharmaceutical company dedicated to advancing therapies for rare, metabolic and life-threatening diseases, announced today that Nevan Charles Elam, the Company’s CEO and founder, will be presenting a corporate overview as part of the upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference. Beginning November 23, the presentation will be available for viewing anytime through December...

    11/5/2020RZLT
    Rezolute Announces Uplisting to the Nasdaq Capital Market

    Trading expected to begin November 9, 2020REDWOOD CITY, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (OCTQB:RZLTD), a clinical stage biopharmaceutical company dedicated to advancing therapies for rare, metabolic and life-threatening diseases, announced today that the Company’s common shares have been approved for listing on the Nasdaq Capital Market (“Nasdaq”). Trading on Nasdaq is expected to begin on Monday, November 9, 2020, under the symbol “RZLT”. The Company’s shares will conti...